diff --git a/pages/STOP2030___Web.md b/pages/STOP2030___Web.md
index 2adeab65..9831eec1 100644
--- a/pages/STOP2030___Web.md
+++ b/pages/STOP2030___Web.md
@@ -48,5 +48,5 @@
 			  This [[project]], [[STOP2030]], seeks to complement the results of the safety and efficacy trial with a field-based safety and effectiveness clinical study, acceptability studies in [[Ghana]] and [[Kenya]], modelling and cost-effectiveness exercises. The resulting information will be consolidated to build a multidisciplinary package for policy making and [[WHO]] guidance with the support of advocacy and communication activities to reach stakeholders and maximize the exploitation and impact of the [[FDC]] for [[STH]] control and elimination. 
 			  
 			  The Consortium assembled to execute the [[STOP2030]] proposal combines expertise in complementary fields [[from]] program assessment and implementation through Ministries of [[Health]] in sub Saharan African countries, advocacy, state of the art technology, leadership in clinical research and a pharma that has shown commitment for generating access to drugs against NTDs and has recently obtained [[WHO]] prequalification for generic ivermectin #INFO
-		- [[Project]] [[duration]] (36 months); cuando empieza y cuando acaba (20 junio 2026)
+		- Project duration (36 months); cuando empieza y cuando acaba (20 junio 2026)
 		-
\ No newline at end of file